Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple ascending dose inhaled MMI-0100 in healthy volunteers
NL-OMON43064Phase 1Active, not recruiting
- Sponsor
- Moerae Matrix, Inc
- Start
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MMI-0100 in idiopathic pulmonary fibrosis (IPF) (8 arms), sponsored by Moerae Matrix, Inc. Primary endpoint: Safety and tolerability of pulmonary administered MMI-0100 after daily dosing for 7 days. Started Mar 2016; status: active, not recruiting.
02
Drugs
MMI-0100
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON43064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43064.